课题基金 / 基金详情

Characterizing Dopamine D2 and D3 Receptor Binding in Treatment Resistant Depression

Characterizing Dopamine D2 and D3 Receptor Binding in Treatment Resistant Depression
难治性抑郁症中多巴胺 D2 和 D3 受体结合的特征
批准号：
389143
负责人：
Rizvi Sakina
金额：
$23.13万
依托单位：
Unity Health Toronto
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2018
资助国家：
加拿大
项目状态：
已结题
起止时间：
2018-09-01 至 2021-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=389143&lang=en
关键词：
Dopamine Receptor Flb 457 Phno Positron Emission Tomography Treatment Resistant Depression

项目摘要

项目成果

Rizvi Sakina的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
It is estimated that 30% of individuals with Major Depressive Disorder (MDD) do not significantly improve with antidepressant medication, accounting for over 1 million Canadians in their lifetime. Treatment resistant depression (TRD), defined as a failure
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
An fMRI study investigating pain processing to understand mechanisms of suicide risk
Mitigating suicide risk during the COVID-19 pandemic via telehealth using an intensive single session of "Brief Skills for Safer Living"
  • 批准号：
    432365
  • 项目类别：
    Operating Grants
  • 资助金额：
    $14.06万
  • 财政年份：
    2020
  • 负责人：
    Rizvi Sakina
  • 依托单位：
    Unity Health Toronto